Treatment of XXXX in the elderly. Part I: @entity1149 .

@entity1 @entity5 @entity2 @entity1149 @entity3 @entity7730
There is a general trend worldwide of an increasing incidence of elderly population. Age is the greatest risk factor for @entity5 ; therefore, this demographic shift is the main reason for an increase of @entity5 incidence. @entity2 is a typical disease of the elderly @entity1 . This review summarizes the issues of treatment of @entity1149 ( @entity1149 ) in the elderly. Early stage @entity1149 is usually treated with radical surgery, locally advanced @entity1149 with radiotherapy (RT) and/or @entity7730 ( @entity7730 ) and @entity3 with @entity7730 , but the evidence for these approaches is based on studies which are usually performed with highly selected @entity1 while elderly @entity1 are under-represented. We used the data from studies addressing particularly elderly or providing subgroup information on age to analyse the feasibility of current standard approaches for elderly and discuss alternative approaches. Surgery is an effective method in elderly @entity1 with early stage @entity1149 although some approaches bear a somewhat higher risk of operative morbidity and mortality. RT for early stage may be an alternative with curative potential. For locally advanced stage RT alone, or combined radiochemotherapy in selected cases, is feasible for elderly @entity1 with locally advanced @entity1149 when a careful assessment of pre-therapeutic status is made and appropriate drugs are selected. Advanced age alone also should not preclude @entity7730 , although the risk of adverse effect may be higher in certain cases. New generation drugs seem to be particularly feasible and efficient in elderly @entity1 . In general, age itself does not seem to preclude @entity1 from standard treatments although in some cases co-morbidity forces to alternative approaches. Currently, single-agent @entity7730 should be considered as the standard treatment of advanced @entity1149 elderly @entity1 .
